Multiple Sclerosis: Shall We Target CD33?
Background: Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS). Myeloid lineage cells (microglia and macrophages) may participate in the pathogenic mechanisms leading to MS. CD33 is a transmembrane receptor, mainly expressed by myeloid lineage cells. CD33 rs3865444 is a...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-11-01
|
| Series: | Genes |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4425/11/11/1334 |
| _version_ | 1797548134080970752 |
|---|---|
| author | Vasileios Siokas Zisis Tsouris Athina-Maria Aloizou Christos Bakirtzis Ioannis Liampas Georgios Koutsis Maria Anagnostouli Dimitrios P. Bogdanos Nikolaos Grigoriadis Georgios M. Hadjigeorgiou Efthimios Dardiotis |
| author_facet | Vasileios Siokas Zisis Tsouris Athina-Maria Aloizou Christos Bakirtzis Ioannis Liampas Georgios Koutsis Maria Anagnostouli Dimitrios P. Bogdanos Nikolaos Grigoriadis Georgios M. Hadjigeorgiou Efthimios Dardiotis |
| author_sort | Vasileios Siokas |
| collection | DOAJ |
| description | Background: Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS). Myeloid lineage cells (microglia and macrophages) may participate in the pathogenic mechanisms leading to MS. CD33 is a transmembrane receptor, mainly expressed by myeloid lineage cells. CD33 rs3865444 is a promoter variant previously associated with Alzheimer’s disease, whose role in MS remains obscure. Objective: To assess the role of CD33 rs3865444 in MS risk. Methods: We genotyped 1396 patients with MS and 400 healthy controls for the presence of the CD33 rs3865444 variant. Odds ratios (ORs) with the respective 95% confidence intervals (CIs), were calculated with the SNPStats software, assuming five genetic models (co-dominant, dominant, recessive, over-dominant, and log-additive), with the G allele as the reference allele. The value of 0.05 was set as the threshold for statistical significance. Results: CD33 rs3865444 was associated with MS risk in the dominant (GG vs. GT + TT; OR (95% C.I.) = 0.79 (0.63–0.99), <i>p</i> = 0.041) and the over-dominant (GG + TT vs. GT; OR (95% C.I.) = 0.77 (0.61–0.97), <i>p</i> = 0.03) modes of inheritance. Given that the GG genotype was more frequent and the GT genotype was less frequent in MS patients compared to controls—while the observed frequency of the TT genotype did not differ between the two groups—the observed difference in MS risk may be stemming from either the GG (as a risk factor) or the GT (as a protective factor) genotype of CD33 rs3865444. Conclusions: Our preliminary results suggest a possible contribution of CD33 rs3865444 to MS. Therefore, larger multiethnic studies should be conducted, investigating the role of CD33 rs3865444 in MS. |
| first_indexed | 2024-03-10T14:55:10Z |
| format | Article |
| id | doaj.art-a897472d0a234b1eb34ad02300e3ee97 |
| institution | Directory Open Access Journal |
| issn | 2073-4425 |
| language | English |
| last_indexed | 2024-03-10T14:55:10Z |
| publishDate | 2020-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Genes |
| spelling | doaj.art-a897472d0a234b1eb34ad02300e3ee972023-11-20T20:41:19ZengMDPI AGGenes2073-44252020-11-011111133410.3390/genes11111334Multiple Sclerosis: Shall We Target CD33?Vasileios Siokas0Zisis Tsouris1Athina-Maria Aloizou2Christos Bakirtzis3Ioannis Liampas4Georgios Koutsis5Maria Anagnostouli6Dimitrios P. Bogdanos7Nikolaos Grigoriadis8Georgios M. Hadjigeorgiou9Efthimios Dardiotis10Laboratory of Neurogenetics, Department of Neurology, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, GreeceLaboratory of Neurogenetics, Department of Neurology, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, GreeceLaboratory of Neurogenetics, Department of Neurology, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, GreeceMultiple Sclerosis Center, B’ Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, GR54636 Thessaloniki, GreeceLaboratory of Neurogenetics, Department of Neurology, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, GreeceNeurogenetics Unit, 1st Department of Neurology, Eginition Hospital, School of Medicine, National and Kapodistrian University of Athens, Vassilissis Sofias 72-74 Ave, 11528 Athens, GreeceMultiple Sclerosis and Demyelinating Diseases Unit and Immunogenetics Laboratory, 1st Department of Neurology, Eginition Hospital, School of Medicine, National and Kapodistrian University of Athens, 115 28 Athens, GreeceDepartment of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, GreeceMultiple Sclerosis Center, B’ Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, GR54636 Thessaloniki, GreeceLaboratory of Neurogenetics, Department of Neurology, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, GreeceLaboratory of Neurogenetics, Department of Neurology, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, GreeceBackground: Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS). Myeloid lineage cells (microglia and macrophages) may participate in the pathogenic mechanisms leading to MS. CD33 is a transmembrane receptor, mainly expressed by myeloid lineage cells. CD33 rs3865444 is a promoter variant previously associated with Alzheimer’s disease, whose role in MS remains obscure. Objective: To assess the role of CD33 rs3865444 in MS risk. Methods: We genotyped 1396 patients with MS and 400 healthy controls for the presence of the CD33 rs3865444 variant. Odds ratios (ORs) with the respective 95% confidence intervals (CIs), were calculated with the SNPStats software, assuming five genetic models (co-dominant, dominant, recessive, over-dominant, and log-additive), with the G allele as the reference allele. The value of 0.05 was set as the threshold for statistical significance. Results: CD33 rs3865444 was associated with MS risk in the dominant (GG vs. GT + TT; OR (95% C.I.) = 0.79 (0.63–0.99), <i>p</i> = 0.041) and the over-dominant (GG + TT vs. GT; OR (95% C.I.) = 0.77 (0.61–0.97), <i>p</i> = 0.03) modes of inheritance. Given that the GG genotype was more frequent and the GT genotype was less frequent in MS patients compared to controls—while the observed frequency of the TT genotype did not differ between the two groups—the observed difference in MS risk may be stemming from either the GG (as a risk factor) or the GT (as a protective factor) genotype of CD33 rs3865444. Conclusions: Our preliminary results suggest a possible contribution of CD33 rs3865444 to MS. Therefore, larger multiethnic studies should be conducted, investigating the role of CD33 rs3865444 in MS.https://www.mdpi.com/2073-4425/11/11/1334multiple sclerosisCD33single nucleotide polymorphismgeneticsrs3865444 |
| spellingShingle | Vasileios Siokas Zisis Tsouris Athina-Maria Aloizou Christos Bakirtzis Ioannis Liampas Georgios Koutsis Maria Anagnostouli Dimitrios P. Bogdanos Nikolaos Grigoriadis Georgios M. Hadjigeorgiou Efthimios Dardiotis Multiple Sclerosis: Shall We Target CD33? Genes multiple sclerosis CD33 single nucleotide polymorphism genetics rs3865444 |
| title | Multiple Sclerosis: Shall We Target CD33? |
| title_full | Multiple Sclerosis: Shall We Target CD33? |
| title_fullStr | Multiple Sclerosis: Shall We Target CD33? |
| title_full_unstemmed | Multiple Sclerosis: Shall We Target CD33? |
| title_short | Multiple Sclerosis: Shall We Target CD33? |
| title_sort | multiple sclerosis shall we target cd33 |
| topic | multiple sclerosis CD33 single nucleotide polymorphism genetics rs3865444 |
| url | https://www.mdpi.com/2073-4425/11/11/1334 |
| work_keys_str_mv | AT vasileiossiokas multiplesclerosisshallwetargetcd33 AT zisistsouris multiplesclerosisshallwetargetcd33 AT athinamariaaloizou multiplesclerosisshallwetargetcd33 AT christosbakirtzis multiplesclerosisshallwetargetcd33 AT ioannisliampas multiplesclerosisshallwetargetcd33 AT georgioskoutsis multiplesclerosisshallwetargetcd33 AT mariaanagnostouli multiplesclerosisshallwetargetcd33 AT dimitriospbogdanos multiplesclerosisshallwetargetcd33 AT nikolaosgrigoriadis multiplesclerosisshallwetargetcd33 AT georgiosmhadjigeorgiou multiplesclerosisshallwetargetcd33 AT efthimiosdardiotis multiplesclerosisshallwetargetcd33 |